Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. (Q50776610)
Jump to navigation
Jump to search
scientific article published on 4 September 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. |
scientific article published on 4 September 2007 |
Statements
1 reference
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. (English)
1 reference
1 reference
1 reference
F Montemurro
1 reference
C Marchiò
1 reference
G Viale
1 reference
M Donadio
1 reference
A Bottini
1 reference
G Botti
1 reference
A Bersiga
1 reference
S Di Palma
1 reference
M Truini
1 reference
G Sanna
1 reference
M Aglietta
1 reference
G Bussolati
1 reference
4 September 2007
1 reference
1 reference
18
1 reference
12
1 reference
1963-1968
1 reference
Identifiers
1 reference
1 reference